Pioglitazone improves insulin sensitivity by reducing muscle lipids and reorganizing lipids in adipose tissue [192], thereby decreasing the risk of major cardiovascular events (myocardial infarction and nonfatal stroke) in patients with prediabetes and diabetes, although it is associated with an increased risk of heart failure, bone fractures, and weight gain [193]. Here, INS is linked to diabetes mellitus.